Patents Assigned to Arisan Therapeutics, Inc.
  • HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS
    Publication number: 20230303569
    Abstract: The invention relates to compounds of structural formula 1 wherein A is independently N or C—R3, R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C6) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: May 11, 2023
    Publication date: September 28, 2023
    Applicant: Arisan Therapeutics Inc.
    Inventors: Nadezda Sokolova, Kenneth McCormack, Gregory Henkel, Vidyasagar Reddy Gantla, Eric Brown
  • Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
    Patent number: 11548893
    Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 10, 2023
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla
  • HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
    Publication number: 20220281825
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Application
    Filed: April 21, 2022
    Publication date: September 8, 2022
    Applicant: Arisan Therapeutics Inc.
    Inventors: Kenneth McCormack, Michael Bruno Plewe, Nadezda Sokolova, Gregory Henkel, Eric Brown, Vidyasagar Reddy Gantla, Young-Jun Shin
  • COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
    Publication number: 20220193038
    Abstract: Compounds as exemplified by compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.
    Type: Application
    Filed: December 3, 2019
    Publication date: June 23, 2022
    Applicant: Arisan Therapeutics Inc.
    Inventors: Eric Brown, Vidyasagar Reddy Gantla, Nadezda Sokolova, Michael Bruno Plewe, Gregory Henkel, Kenneth McCormack
  • Heterocyclic compounds for the treatment of arenavirus
    Patent number: 11352328
    Abstract: The invention relates to compounds of structural formula I wherein A, D, and E are independently N or C—R3, G, H, and J are independently N or C, K is N or C—H, L is N, N—R3 or C—R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: June 7, 2022
    Assignee: Arisan Therapeutics Inc.
    Inventors: Michael Plewe, Eric Brown, Vidyasagar Gantla, Gregory Henkel, Kenneth McCormack, Nadzeda V. Sokolova, Young-Jun Shin
  • ENANTIOMERICALLY PURE ADAMANTANE CARBOXAMIDES FOR THE TREATMENT OF FILOVIRUS INFECTION
    Publication number: 20210171521
    Abstract: The compounds of the invention as shown by general structure I, as shown below, are effective in treating filovirus infections. X is selected from the group consisting of O and H; R1 is selected from (C6 to C10) aryl and (C2 to C9) heteroaryl, and R2 is selected from (C1 to C10) alkyl, (C1 to C10) alkenyl, (C1 to C10) alkynyl, (C3 to C10) cycloalkyl, and (C5 to C10) cycloalkenyl, and NR3aR3b is defined in the specification. These compounds are effective in treating filovirii infections including Ebolavirus and Marburg virus.
    Type: Application
    Filed: July 11, 2018
    Publication date: June 10, 2021
    Applicant: Arisan Therapeutics, Inc.
    Inventors: Michael Bruno Plewe, Kenneth McCormack, Gregory Henkel, Nadezda V. Sokolova, Eric Brown, Vidyasagar Reddy Gantla